Royalty Debt To Assets from 2010 to 2024

RPRX Stock  USD 26.60  0.31  1.18%   
Royalty Pharma Debt To Assets yearly trend continues to be fairly stable with very little volatility. Debt To Assets are likely to outpace its year average in 2024. During the period from 2010 to 2024, Royalty Pharma Debt To Assets regression line of annual values had r-squared of  0.37 and arithmetic mean of  0.50. View All Fundamentals
 
Debt To Assets  
First Reported
2010-12-31
Previous Quarter
0.3745172
Current Value
0.52
Quarterly Volatility
0.0915551
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 196.5 M, Total Revenue of 2.5 B or Research Development of 57.5 M, as well as many indicators such as Price To Sales Ratio of 5.07, Dividend Yield of 0.0361 or PTB Ratio of 3.83. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Debt To Assets Growth Pattern

Below is the plot of the Debt To Assets of Royalty Pharma Plc over the last few years. It is Royalty Pharma's Debt To Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.
Debt To Assets10 Years Trend
Slightly volatile
   Debt To Assets   
       Timeline  

Royalty Debt To Assets Regression Statistics

Arithmetic Mean0.50
Geometric Mean0.49
Coefficient Of Variation18.18
Mean Deviation0.07
Median0.55
Standard Deviation0.09
Sample Variance0.01
Range0.3223
R-Value(0.61)
Mean Square Error0.01
R-Squared0.37
Significance0.02
Slope(0.01)
Total Sum of Squares0.12

Royalty Debt To Assets History

2024 0.52
2023 0.37
2022 0.42
2021 0.41
2020 0.28
2019 0.5
2018 0.57

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Debt To Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Assets 0.37  0.52 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.